Adrian Rawcliffe, Adaptimmune CEO
September 9, 2022 10:30 AM EDTUpdated 10:51 AM
R&D
Cell/Gene Tx

#ES­MO22: Adap­ti­m­mune touts new PhI da­ta for its cell ther­a­py treat­ment

Tyler Patchen

News Reporter

As the cell ther­a­py biotech Adap­ti­m­mune has been ea­ger to present da­ta to progress with the FDA, the com­pa­ny hopes that its lat­est show­ing at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times